Cernostics is focused on delivering the next generation of cancer diagnostics & prognostics through a unique approach to tissue analysis.

Learn about our approach...

Barrett's Esophagus & Esophageal Cancer

Three million people in the U.S. have Barrett's Esophagus, a known precursor to esophageal cancer. Until now, identifying which patients are at greatest risk for esophageal cancer has been impossible. Cernostics is looking to change that… Learn how
News
View All News
03/21/2018
Cernostics Raises $2.5 Million in Series A1 Financing, Led by Illumina Ventures... Read More
09/22/2017
Cernostics Announces Leadership Team Expansion... Read More
10/11/2016
New TissueCypher® Validation Study identifies high risk Barrett’s Esophagus patients who are 46x more likely to have cancer at time of biopsy... Read More
Events
01/09/2017 — San Francisco, CA
JP Morgan Healthcare Conference
05/06/2017 — Chicago, IL
Digestive Disease Week
10/13/2017 — Orlando, FL
American College of Gastroenterology
Customer Service

Mon-Fri 9am-5pm (EST)

Email 412-820-3050
×